The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).
 
Edmond Michael Kwan
Honoraria - Astellas Pharma; Ipsen; Janssen; Research Review
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Pfizer; Roche
 
Michael S Hofman
Consulting or Advisory Role - Janssen; MSD; Novartis (Inst)
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Debiopharm Group (Inst); Novartis
 
Sarah WS Ng
No Relationships to Disclose
 
Louise Emmett
Consulting or Advisory Role - Clarity Pharmaceuticals; Noxopharm
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
James Patrick Buteau
No Relationships to Disclose
 
Amir Iravani
No Relationships to Disclose
 
Anthony M. Joshua
Stock and Other Ownership Interests - Opthea; Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Medison (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Roslyn J. Francis
Employment - AIQ Solutions (I)
Stock and Other Ownership Interests - AIQ Solutions (I)
Consulting or Advisory Role - AIQ Solutions (Inst)
Research Funding - AIQ Solutions (Inst)
 
Vinod Subhash
No Relationships to Disclose
 
Sze Ting Lee
No Relationships to Disclose
 
Andrew Mark Scott
Stock and Other Ownership Interests - Certis Therapeutics; Paracrine Therapeutics
Consulting or Advisory Role - Imagion Biosystems; ImmunOs Therapeutics
Research Funding - Adalta (Inst); Antengene (Inst); AstraZeneca (Inst); AVID/Lilly (Inst); Curis (Inst); Cyclotek (Inst); EMD Serono (Inst); Fusion Pharmaceuticals (Inst); Humanigen (Inst); Isotopen Technologien (Inst); Merck (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patents relating to antibodies to EGFR, HER2, PDGF-CC, FN-14, GM-CSF, EPhA3 (Inst)
 
Andrew James Martin
No Relationships to Disclose
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Gráinne Donnellan
No Relationships to Disclose
 
Matti Annala
Leadership - Fluivia
Stock and Other Ownership Interests - Fluivia
 
Sofie H. Tolmeijer
Honoraria - Bayer
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Alexander William Wyatt
Honoraria - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Janssen; Merck; Pfizer
Research Funding - ESSA (Inst); Tyra Biosciences (Inst)